BioSpace News Archive

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2020.

Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $241.3 million, or $2.82 per diluted share, during the third quarter of 2020, as compared to $97.2 million, or $1.10 per diluted share, during the comparable quarter of 2019

Rafael Holdings, Inc., reported revenue of $4.9 million and a loss per share of $0.66 for the fiscal year ended July 31, 2020.

Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day. A live, listen-only webcast wi

Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2020. “Tilsotolimod is the most advanced TLR-9 agonist therapy in development, and we have made tremendous strides against our objectives for 2020,” stated Vincent Milano, Idera’s Chief Executive Officer. “We continue to work diligently against our timelines for ILLUMINATE-301, which

Dyadic International, Inc. announced that it will report its financial results for quarter ended September 30, 2020 after the market close on Thursday, November 12, 2020 and it will host a conference call that day at 5:00 p.m.

How the Pacific Northwest accelerates and amplifies the growth and diversity of our life science and biotech clusters will be under the microscope at the Oregon Bio Digital 2020: Amplifying Diversity of Discovery, Access and Economics Conference.

Emmes announced that the Montgomery County Chamber of Commerce has selected Emmes as the recipient of its 2020 Corporate Achievement Award.

Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™ ¥ . “Nexus Pharmaceuticals is very pleased to announce the approval of Succinylcholine Chloride. This critical need drug has seen an increased demand due to the COVID-19 pandemic and Nexus will be read

Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warran